Short children born small for gestational age (SGA) may be candidates for treatment with growth hormone (GH). We examined craniofacial growth and dental maturation in a cohort of short SGA children. The general growth failure of these children is reflected to a differential extent within the craniofacial complex. As a group, these children have a small retrognathic face with a relatively increased lower anterior face height; in contrast to skeletal maturation, dental age is not delayed. GH treatment in short prepubertal SGA children leads to craniofacial catch-up growth, which is particularly pronounced in regions where interstitial cartilage is involved, the result being that the facial profile becomes less convex; dental maturation does not appear to be influenced by GH treatment. In conclusion, in short SGA children, GH treatment does not only result in an increase of body stature but also in a trend towards normalization of craniofacial growth and this without notable advancement of dental maturation.

Keywords:
Growth hormone, Intrauterine growth retardation, Craniofacial growth, Cephalometry, Dental maturation, Bone maturation, Longitudinal study
1.
Gluckman PD: Fetal growth: An endocrine perspective. Acta Paediatr Scand 1989;349(suppl):21–24.
2.
Platt LD: Genetic factors in intrauterine growth retardation. Semin Perinatol 1988;12:11–16.
3.
Fitzhardinge PM, Steven EM: The small-for-date infant. II. Neurologic and intellectual sequelae. Pediatrics 1972;50:50–57.
4.
Barker DJP, Osmond C, Golding J, Kuh D, Wadsworth MEJ: Growth in utero, blood pressure in childhood and adult life, and mortality from cardiovascular disease. BMJ 1989;298:564–567.
5.
Phillips DIW, Barker DJP, Hales CN, Hirst S, Osmond C: Thinness at birth and insulin resistance in adult life. Diabetologia 1994;37:150–154.
6.
de Zegher F, Francois I, Van Helvoirt M, Van Den Berghe G: Small as fetus and short as child: From endogenous to exogenous growth hormone. J Clin Endocrinol Metab 1997;82:2021–2026.
7.
Hokken-Koelega AC, De Ridder MA, Lemmen RJ, Den Hartog H, De Muinck Keizer-Schrama SM, Drop SL: Children born small for gestational age: Do they catch up? Pediatr Res 1995;38:267–271.
8.
Karlberg J, Albertsson-Wikland K: Growth in full-term small-for-gestational-age infants: From birth to final height. Pediatr Res 1995;38:733–739.
9.
Ranly DM: Craniofacial Growth – Longitudinal Description: A Synopsis of Craniofacial Growth, ed 2. Norwalk, Appleton & Lange, 1984, pp 124–141.
10.
Van Erum R, Mulier G, Carels C, de Zegher F: Short stature of prenatal origin: Craniofacial growth and dental maturation. Eur J Orthod 1998;20:417–426.
11.
Buschang PH, Baume RM, Nass GG: A craniofacial growth maturity gradient for males and females between 4 and 16 years of age. Am J Phys Anthropol 1983;61:373–381.
12.
Spiegel R, Sather H, Hayles A: Cephalometric study of children with various endocrine diseases. Am J Orthod 1971;59:362–375.
13.
Poole A, Greene I, Buschang P: The effect of growth hormone therapy on longitudinal growth of the oral facial structures in children; in Dixon A, Sarnat B (eds): Factors and Mechanisms Influencing Bone Growth. New York, Liss, 1982, pp 499–516.
14.
Pirinen S, Majurin A, Lenko H-L, Koski K: Craniofacial features in patients with deficient and excessive growth hormone. J Craniofac Genet Dev Biol 1994;14:144–152.
15.
Kotilainen J, Hölttä P, Mikkonen T, Arte S, Sipilä I, Pirinen S: Craniofacial and dental characteristics of Silver-Russell syndrome. Am J Med Genet 1995;56:229–236.
16.
van den Eynde B, Kjaer I, Solow B, Graem N, Kjaer TW, Mathiesen M: Cranial base angulation and prognathism related to cranial and general skeletal maturation in human fetuses. J Craniofac Genet Dev Biol 1992;12:22–32.
17.
Ohtsuki F, Mukherjee D, Lewis AB, Roche AF: A factor analysis of cranial base and vault dimensions in children. Am J Phys Anthropol 1982;58:271–279.
18.
Shuper A, Shahat M, Sarnat H, Varsano I, Mimouni M: Deciduous tooth eruption in children who fail to gain weight. Helv Paediatr Acta 1986;41:501–504.
19.
Lewis AB: Comparisons between dental and skeletal ages. Angle Orthod 1990;61:87–92.
20.
Tanner JM, Whitehouse RH, Hughes PCR, Vince FP: Effect of human growth hormone for one to seven years on growth of 100 children, with growth hormone deficiency, low birth weight, inherited smallness, Turner’s syndrome and other complaints. Arch Dis Child 1971;46:745–782.
21.
Grunt JA, Enriquez AR, Daughaday WH, Budd S: Acute and long-term responses to hGH in children with idiopathic small-for-dates dwarfism. J Clin Endocrinol Metab 1972;35:157–168.
22.
Foley TP Jr, Thompson RG, Shaw M, Baghdassavian A, Nissley SP, Blizzard RM: Growth responses to human growth hormone in patiens with intra-uterine growth retardation. J Pediatr 1974;84:635–641.
23.
Lanes R, Plotnick LP, Lee PA: Sustained effect of human growth hormone therapy on children with intrauterine growth retardation. Pediatrics 1979;63:731–735.
24.
Stanhope R, Preece MA, Hamil G: Does growth hormone treatment improve final height attainment of children with intrauterine growth retardation? Arch Dis Child 1991;66:1180–1183.
25.
Chatelain P, Job JC, Blanchard J, Ducret JP, Olivier M, Sagnard L, Vanderschueren-Lodeweyckx M: Dose-dependent catch-up growth after 2 years of growth hormone treatment in intrauterine growth-retarded children. J Clin Endocrinol Metab 1994;78:1454–1460.
26.
de Zegher F, Maes M, Gargosky SE, Heinrichs C, Du Caju MVL, Thiry G, De Schepper J, Craen M, Breysem L, Löfström A, Jönsson P, Bourguignon JP, Malvaux P, Rosenfeld RG: High-dose growth hormone treatment of short children born small for gestational age. J Clin Endocrinol Metab 1996;81:1887–1892.
27.
de Zegher F, François I, Van Helvoirt M, Beckers D, Ibáñez L, Chatelain P: Growth hormone treatment of short children born small for gestational age. Trends Endocrinol Metab 1998;9:233–237.
28.
de Zegher F, Albertsson-Wikland K, Wilton P, Chatelain P, Jonsson B, Löfström A, Butenandt O, Chaussain JL: Growth hormone treatment of short children born small for gestational age: Metanalysis of four randomized, controlled, multicentre studies. Acta Paediatr 1996(suppl 417):27–31.
29.
Van Erum R, Mulier G, Carels C, Verbeke G, de Zegher F: Craniofacial growth in short children born small for gestational age: Effect of growth hormone treatment. J Dent Res 1997;76:1579–1586.
30.
Garn SM, Lewis AB, Blizzard RM: Endocrine factors in dental development. J Dent Res 1965(suppl):243–258.
31.
Keller EE, Sather AH, Hayles AB: Dental and skeletal developmental in various endocrine and metabolic diseases. J Am Dent Assoc 1970;81:415–419.
32.
Bevis RR, Hayles AB, Isaacson RJ, Sather AH: Facial growth response to human growth hormone in hypopituitary dwarfs. Angle Orthod 1977;47:193–205.
33.
Myllarniemi S, Lenko HL, Perheentupa J: Dental maturity in hypopituitarism and dental response to substitution treatment. Scand J Dent Res 1978;86:307–312.
34.
Van Erum R, Carels C, Verbeke G, de Zegher F: Craniofacial growth in short children born small for gestational age: Two years’ follow-up after high-dose growth hormone traetment. J Craniofac Genet Dev Biol 1997;17:184–189.
35.
Karlberg P, Taranger J, Engstrom I, Lichtenstein H, Svennberg-Redegren I: The somatic development of children in a Swedish urban community. Acta Paediatr Scand 1976;258:(suppl):7–76.
1998
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.